Loading...
Market
What will be the next major milestone for CAN-2409 by end of 2025?
2
Resolution / Starting Odds
Initiation of Phase 4 trial • 25%
Regulatory approval in Europe • 25%
Launch of a new indication study • 25%
No major milestone announced • 25%
Official announcements from Candel Therapeutics
Story
Candel Therapeutics' CAN-2409 Succeeds in Phase 3 Prostate Cancer Trial, Shares Soar
Dec 11, 2024, 12:48 PM
Candel Therapeutics announced that its experimental immunotherapy, CAN-2409, met the primary endpoint in a Phase 3 trial for prostate cancer, showing significantly improved disease-free survival. Following the announcement, the company's shares more than doubled in value in premarket trading. CAN-2409 is an oncolytic virus designed to stimulate the immune system to attack cancer cells. The trial's success marks a significant milestone for Candel Therapeutics, potentially paving the way for further development and regulatory approval of the treatment.
View original story
Similar markets
Progress to Phase 2 • 25%
Significant efficacy results • 25%
Safety concerns emerge • 25%
No significant milestone • 25%
Phase 2 trial results • 25%
Partnership announcement • 25%
Regulatory submission • 25%
Other milestone • 25%
Phase 2 completion • 25%
Phase 3 initiation • 25%
Regulatory approval submission • 25%
No significant milestone • 25%
Phase 1 completion • 25%
Phase 2 initiation • 25%
Partnership announcement • 25%
Other milestone • 25%
Phase 2 Clinical Trial Approval • 25%
Breakthrough Therapy Designation • 25%
Priority Review Designation • 25%
Other • 25%
Increased power output • 25%
Miniaturization for smaller platforms • 25%
Integration with autonomous systems • 25%
Other advancements • 25%
Adoption in top AI research labs • 25%
Integration in top tech companies' products • 25%
Winning a major AI benchmark contest • 25%
Other • 25%
Secures Series A funding • 25%
Announces major partnership • 25%
Publishes groundbreaking research • 25%
Other • 25%
Achieving 95% accuracy in basic tasks • 25%
Integration into commercial robots • 25%
Adoption in healthcare • 25%
Other • 25%
Phase 1 completion • 25%
Phase 2 completion • 25%
Phase 3 completion • 25%
No significant milestone • 25%
Completion of Site Preparation • 25%
Start of Construction • 25%
First Major Funding Round • 25%
Partnership with New Stakeholders • 25%
Coverage expansion announcement • 25%
New service launch • 25%
Technical upgrade • 25%
Other • 25%